Voyager Therapeutics, Inc. VYGR R2K

Q: What is the current share price of Voyager Therapeutics, Inc. (VYGR)?

As of 2026-07-14 21:23 PDT, Voyager Therapeutics, Inc. (VYGR) trades at $3.16 on NasdaqGS. Its 52-week range is $2.96 to $5.33.

Q: What is the market capitalisation of VYGR?

Voyager Therapeutics, Inc. (VYGR) has a market capitalisation of $190.93M on NasdaqGS.

Q: What is the P/E ratio of VYGR?

VYGR trades at a trailing price-to-earnings (P/E) ratio of -1.58. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.31.

Q: What is the return on equity (ROE) of VYGR?

VYGR has a return on equity (ROE) of -52.26%. Its return on capital employed (ROCE) is -58.41%.

Q: Is VYGR a good stock to buy?

This page provides a data-driven analysis of Voyager Therapeutics, Inc. (VYGR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.voyagertherapeutics.com

Company Profile ↓

$3.16

-7.87% 1Y

Mkt Cap$190.93M

P/E-1.58

P/B1.31

52W High$5.33

52W Low$2.96

Book Value$2.88

EPS (TTM)$-2.00

Company Overview

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.20.

Recent Developments

Dec 2025 Revenue of $40.37M (-49.5% YoY); net profit $-119.72M.
Trailing 12 Months Year-on-year growth — revenue -59.9%.
5-Year Trend Long-term compounding — revenue CAGR -0.4%, profit CAGR -52.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	-0.44%
1 Year:	-59.90%

Compounded Profit Growth

5 Years:	-52.66%
1 Year:	-

Stock Price Performance

1 Year:	-7.87%
6 Months:	-21.39%
3 Months:	-17.71%
1 Month:	-8.67%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 8% of range

$2.96 $5.33

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)34.70 · Neutral

Price Performance

1M-8.67%

3M-17.71%

6M-21.39%

1Y-7.87%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

Revenue declined at -0.4% CAGR over 5 years.
Earnings shrank at -52.7% CAGR over 5 years.
Trading 40.7% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-1.58

Industry PE

25.41

Forward P/E

-2.03

PEG Ratio

Book Value

$2.88

Price to Book

1.31

P/S

6.24

EV/EBITDA

-1.01

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

-0.44%

Profit 5Y

-52.66%

Revenue (YoY)

-59.90%

Earnings (YoY)

Profitability & Returns

ROCE

-58.41%

ROE

-52.26%

ROA

-27.05%

Profit Margin

0.00%

Op Margin

Gross Margin

EPS (Latest Qtr)

$-0.47

EPS (TTM)

$-2.00

Balance Sheet & Liquidity

Debt/Equity

0.20

Quick Ratio

8.20

Current Ratio

8.42

Debt

$34.57M

Total Assets

$219.32M

Current Assets

$146.98M

Working Capital

$176.15M

Ownership

Promoter Holding

15.14%

Chg in Prom Hold

FII / Inst Holding

56.44%

Chg in FII Hold

0.00%

Financial Snapshot

Enterprise Value

$190.93M

Total Revenue (TTM)

$36.49M

EBITDA

$-119.94M

Free Cash Flow

$-80.83M

Operating Cash Flow

$-127.99M

Shares Outstanding

60.42M

Gross Margin

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	VYGR Voyager Therapeutics, Inc. R2K	3.16	-1.58	$190.93M	0.00%	-58.41%	-52.26%	-0.44%	-52.66%
2	LLY Eli Lilly and Company SPX	1,152.54	41.02	$1.03T	0.61%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	253.85	29.45	$611.07B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.78	119.40	$432.48B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	425.19	32.02	$386.13B	2.27%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	120.78	34.02	$298.31B	2.86%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	164.50	24.81	$255.12B	1.77%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	534.07	29.33	$198.47B	0.40%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	355.25	24.69	$191.73B	2.84%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	1.46M	1.18M	1.15M	6.35M	942.00K	2.58M	2.09M	2.01M	5.20M	46.09M	20.43M	32.67M	18.07M	28.68M	117.84M	6.50M	1.36M	1.48M	658.00K	712.00K	41.09M	150.48M	4.85M	4.61M	19.52M	29.58M	24.63M	6.47M	5.20M	13.37M	15.34M	2.59M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	41.17M	41.83M	43.96M	45.27M	32.86M
Operating Income	-4.83M	-3.97M	-4.02M	-7.44M	-7.47M	-9.62M	-10.37M	-13.84M	-17.52M	-18.64M	-23.36M	-12.35M	-21.09M	-25.69M	-21.15M	-23.16M	-29.29M	9.19M	-17.81M	-13.77M	-24.43M	-8.98M	84.53M	-25.59M	-28.59M	-25.15M	-21.35M	-19.37M	14.44M	122.88M	-25.43M	-29.51M	-16.18M	-15.03M	-13.78M	-34.69M	-36.62M	-30.59M	-29.93M	-30.27M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-33.68M	-35.56M	-29.66M	-28.88M	-29.34M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-30.98M	-33.37M	-27.81M	-27.42M	-27.92M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	37.00K	15.00K	83.00K	9.00K	14.00K
Net Income	-14.58M	-3.90M	-3.92M	-	-7.19M	-9.34M	-9.00M	-	-16.65M	-18.88M	-23.35M	-11.83M	-19.93M	-25.54M	-20.29M	-22.53M	-27.17M	11.15M	-15.01M	-12.57M	-24.26M	-8.68M	85.61M	-21.65M	-30.12M	-25.14M	-21.32M	-19.09M	17.62M	124.04M	-22.21M	-25.90M	-11.33M	-10.14M	-9.04M	-31.02M	-33.38M	-27.89M	-27.43M	-27.94M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.80	-	-	-	0.29	-0.41	-	-	-0.23	2.27	-0.58	-0.80	-0.67	-0.56	-0.50	0.45	2.94	-0.51	-0.59	-0.20	-0.18	-0.16	-0.53	-0.57	-0.47	-0.47	-0.47
R&D Expense	5.52M	6.46M	6.48M	-	8.73M	10.48M	10.31M	-	14.07M	15.30M	19.56M	-	14.85M	16.51M	16.63M	-	24.83M	28.58M	29.78M	-	32.29M	29.42M	25.04M	22.35M	19.50M	17.91M	14.35M	12.53M	19.34M	18.57M	21.98M	25.86M	27.09M	34.45M	30.24M	31.53M	31.33M	35.87M	-	24.60M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	17.33M	14.22M	10.13M	7.62M	104.39M	171.13M	37.41M	40.91M	250.01M	80.00M	40.37M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	91.74M	127.99M	163.29M	172.22M
Operating Income	-14.37M	-20.25M	-41.30M	-71.86M	-91.09M	-51.68M	27.38M	-73.62M	-50.84M	122.01M	-83.29M	-131.84M
EBITDA	-	-	-	-	-	-	-	-	-44.65M	126.45M	-78.56M	-127.78M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-46.39M	133.74M	-64.34M	-119.58M
Tax Provision	-	-	-	-	-	-	-	-	16.00K	1.41M	665.00K	144.00K
Net Income	-16.32M	-29.67M	-40.19M	-70.70M	-88.29M	-43.60M	36.74M	-71.20M	-46.41M	132.33M	-65.00M	-119.72M
Diluted EPS	-	-	-	-	-2.75	-1.21	0.98	-1.89	-1.21	2.97	-1.13	-2.04
R&D Expense	8.90M	27.68M	42.25M	62.26M	64.91M	119.73M	108.75M	73.79M	60.76M	92.17M	127.37M	134.67M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	11.50M	229.46M	189.57M	184.48M	177.03M	354.76M	261.58M	-	159.36M	351.28M	393.05M	252.28M
Current Assets	-	-	-	-	-	-	-	-	-	124.50M	319.68M	276.81M	202.69M
Cash & Equivalents	135.00K	7.04M	31.31M	36.64M	31.53M	46.86M	86.04M	104.44M	-	98.96M	68.80M	71.37M	65.30M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	0	80.15M	1.50M	1.76M
Total Liabilities	-	10.35M	60.38M	53.64M	50.43M	130.58M	255.25M	107.26M	-	100.34M	114.96M	93.29M	56.20M
Current Liabilities	-	2.47M	23.93M	13.80M	15.90M	31.67M	76.01M	26.77M	-	72.59M	64.51M	49.79M	26.54M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	23.13M	20.29M	43.73M	36.50M
Total Equity	-3.83M	-20.83M	169.07M	135.92M	134.05M	46.45M	99.51M	154.32M	-	59.02M	236.32M	299.76M	196.08M
Shares Outstanding	-	-	-	-	-	-	-	-	-	38.61M	44.04M	54.73M	59.05M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	41.30M	-42.48M	-61.35M	-15.89M	48.67M	-96.72M	-	-12.51M	77.92M	-15.31M	-132.47M
Investing Cash Flow	-	-194.77M	47.72M	-3.68M	26.47M	-90.48M	113.00M	-	-7.34M	-141.64M	-94.86M	125.45M
Financing Cash Flow	-	177.74M	514.00K	59.92M	4.75M	80.99M	3.16M	-	1.11M	33.65M	114.02M	816.00K
Capital Expenditure	-2.99M	-1.03M	-5.03M	-3.98M	-4.30M	-7.72M	-12.10M	-	-2.49M	-3.26M	-3.52M	-2.60M
Free Cash Flow	-	40.27M	-47.51M	-65.33M	-20.19M	40.95M	-108.81M	-	-15.00M	74.66M	-18.83M	-135.06M
Net Change in Cash	-	-	-	-	-	-	-	-	-18.74M	-30.08M	3.85M	-6.21M

Ratios (Annual)

Figures in %.

Metric	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-116.8%	-290.4%	-709.1%	-1,195.6%	-49.5%	16.0%	-196.8%	-124.3%	48.8%	-104.1%	-326.6%
Net Margin %	-	-171.2%	-282.7%	-697.6%	-1,158.8%	-41.8%	21.5%	-190.3%	-113.4%	52.9%	-81.3%	-296.5%
ROE %	78.3%	-17.5%	-29.6%	-52.7%	-190.1%	-43.8%	23.8%	-	-78.6%	56.0%	-21.7%	-61.1%
ROCE %	-159.2%	-9.9%	-23.5%	-42.6%	-62.7%	-18.5%	11.7%	-	-58.6%	42.5%	-24.3%	-58.4%

Shareholding Pattern

Insiders

15.14%

Institutions

56.44%

Public Float

66.50%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	9.22%	5.57M	$20.99M
2	Armistice Capital, LLC	5.79%	3.50M	$13.19M
3	Millennium Management Llc	5.67%	3.43M	$12.92M
4	Vestal Point Capital, LP	4.97%	3.00M	$11.32M
5	Vanguard Capital Management LLC	3.78%	2.28M	$8.60M
6	Opaleye Management Inc.	1.90%	1.15M	$4.33M
7	Erste Asset Management GmbH	1.81%	1.10M	$4.13M
8	Geode Capital Management, LLC	1.74%	1.05M	$3.96M
9	State Street Corporation	1.57%	948.23K	$3.57M
10	Dimensional Fund Advisors LP	1.45%	875.57K	$3.30M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for VYGR

Google News ue, 14 Jul 2026

Voyager Therapeutics Drops To US$3.24, Yet Insiders May Have Sold Too Early - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxNMk5GTUVSRVk5TUJjdmpnZl9JeTVaWnk0M0xReEQtMVg4WHFWdjVZNncwdlNrdGpYcmJlR1JISjhLQVdwY1ZHb1JnZjFkWEQ3alh3ZzNsMW0wUDBEanZseEtDWXVnN1BVZnc2bFh1V3oxNUVHS2NBNTlXOEtac19mb2tGY0NvNFg2TEplX3…

Google News Wed, 15 Jul 2026

Wedbush Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $8 - Moomoo

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOMU9KdHJhWU4wcUQ4ZmtVQ3dsdmhWdnl0eU5TTVdXZXFDOU03SlNNNm1JLXdTVVdyc0x2bmM1d2tsbWhEc0dHWi1hV2hCUEt5X3RyRnNHQl8taDNoUFZ6WThhbDN5MWc0QnpoMGxyTUR0eTJuSi1Mb2ZER1prUGZvWnBJVmVwNU1aWm5nWX…

Google News Sat, 27 Jun 2026

VYGR Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5MY2pyYnpOeGhRQjNLNHJHMzFBbE4zcUNNSF9uNFlldDJEeWZGbVVFWWMycnN0OXNCQ1A2c1NqTmdXTFFHVmJyaHhXalJYR2Q0ZDdpSHR1TWhkSVcydjViQzA5MUtUNG5CYm9uMmZZdjVwakVVN0dnWk9n?oc=5" target="_blank">VYG…

Google News Mon, 13 Jul 2026

[8-K] Voyager Therapeutics, Inc. Reports Material Event - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxPUkN5eGJKZ1k4SzljTjcwTXlLOUNfeE9mS2lxLXlraFB1eFpIaTZtcWd2ZXlvSkVVR0tOTXBGbjF1emxKa2UycmcxTUVlNzRJRDZqUzRsQU1pX0hXTGNpQlRibGNzWUFRbmN1alNzWGRnT2FmY0dpdjYzb0NWOGgwZFNDenpMWWY0OHpHLX…

Google News Mon, 13 Jul 2026

Voyager Therapeutics (VYGR) Reports Promising VY1706 Data for Al - GuruFocus

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPdGw5WktKcEY1X0trZTRZbHRxVHVldThmeXIwcXZpc2pVa0hXSzFOczBaYkVza01fLTdPTGhLa1FscjhyZWZtdjY2NVRRTmpDMmc0bWhyMndpcGdWc2pKRWV2dkhsbWJnNXExMVdmN2lPZ0dBdzMyLUNLQUN5X3pHVTNWMjVTem5Fc1NNVl…

Google News ue, 30 Jun 2026

Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQd3B4X1BKanhGN3VDUlctOTRGM094QWxycXlkM2wtdXJreHFRX3ZjNkQ3SEhqajlyODM3WnZmVWRhdlNVRmVacGFaMXF3OXpNYTZieWRCSjZYVjFkTHRwaklpV1VJM2lpNHh5andreldrb29LQVVzNVNOQlJneWcybENyZEN0bXV2QW9XcH…

VYGR — Frequently Asked Questions

What is the current share price of Voyager Therapeutics, Inc. (VYGR)?

As of 2026-07-14 21:23 PDT, Voyager Therapeutics, Inc. (VYGR) trades at $3.16 on NasdaqGS. Its 52-week range is $2.96 to $5.33.

What is the market capitalisation of VYGR?

Voyager Therapeutics, Inc. (VYGR) has a market capitalisation of $190.93M on NasdaqGS.

What is the P/E ratio of VYGR?

VYGR trades at a trailing price-to-earnings (P/E) ratio of -1.58. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.31.

What is the return on equity (ROE) of VYGR?

VYGR has a return on equity (ROE) of -52.26%. Its return on capital employed (ROCE) is -58.41%.

Is VYGR a good stock to buy?

This page provides a data-driven analysis of Voyager Therapeutics, Inc. (VYGR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Voyager Therapeutics, Inc. VYGR R2K

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Voyager Therapeutics Drops To US$3.24, Yet Insiders May Have Sold Too Early - simplywall.st

Wedbush Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $8 - Moomoo

VYGR Forecast — Price Target — Prediction for 2027 - TradingView

[8-K] Voyager Therapeutics, Inc. Reports Material Event - Stock Titan

Voyager Therapeutics (VYGR) Reports Promising VY1706 Data for Al - GuruFocus

Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside - Yahoo Finance

VYGR — Frequently Asked Questions

What is the current share price of Voyager Therapeutics, Inc. (VYGR)?

What is the market capitalisation of VYGR?

What is the P/E ratio of VYGR?

What is the return on equity (ROE) of VYGR?

Is VYGR a good stock to buy?

Explore More